Current European League Against Rheumatism guidelines strongly recommend considering the use of polysaccharide pneumococcal vaccine in all patients with autoimmune inflammatory rheumatic diseases. However, a previously published case series reports of reactions to 23-valent pneumococcal polysaccharide vaccine in patients with Behcet’s disease. The purpose of this report is to present a similar case of a systemic adverse reaction in a patient with Behcet’s disease to 23-valent pneumococcal polysaccharide vaccine.
DavatchiFShahramFChams-DavatchiCet al.Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis2010; 13: 367–373.
2.
Van AssenSAgmon-LevinNElkayamOet al.EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis2011; 70: 414–422.
3.
DireskeneliH. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis2001; 60: 996–1002.
4.
De MenthonMLaValleyMPMaldiniCet al.HLA–B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case–control genetic association studies. Arthritis Rheum2009; 61: 1287–1296.
5.
LittleMANightingalePVerburghCAet al.Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis2010; 69: 1036–1043.
6.
HügleTBircherAWalkerUA. Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behçet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology2012; 51: 761–762.
